Citation Impact
Citing Papers
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
2017 Standout
Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes
2018 StandoutScienceNobel
Preferential Generation of Follicular B Helper T Cells from Foxp3 + T Cells in Gut Peyer's Patches
2009 StandoutScienceNobel
Generation of knock-in primary human T cells using Cas9 ribonucleoproteins
2015 StandoutNobel
Selective blockade of the inhibitory Fcγ receptor (FcγRIIB) in human dendritic cells and monocytes induces a type I interferon response program
2007 StandoutNobel
Modulation of immune cell reactivity with cis -binding Siglec agonists
2021 StandoutNobel
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
2009 StandoutScience
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
2015 StandoutScience
A sex-biased imbalance between Tfr, Tph, and atypical B cells determines antibody responses in COVID-19 patients
2023 StandoutNobel
Construction of self-recognizing regulatory T cells from conventional T cells by controlling CTLA-4 and IL-2 expression
2013 StandoutNobel
Tumor imaging by means of proteolytic activation of cell-penetrating peptides
2004 StandoutNobel
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
2019 StandoutNobel
Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs β-Cell Function
2012
Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect
2012
Membrane curvature regulates the spatial distribution of bulky glycoproteins
2022 StandoutNobel
PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy
2017
Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections
2005 StandoutNatureNobel
Androgen receptor: A key molecule in the progression of prostate cancer to hormone independence
2003
Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis
2011
Regulation of antitumour immunity by CD1d-restricted NKT cells
2004
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
2012 Standout
The Androgen Receptor Recruits Nuclear Receptor CoRepressor (N-CoR) in the Presence of Mifepristone via Its N and C Termini Revealing a Novel Molecular Mechanism for Androgen Receptor Antagonists
2004
Trial Watch: Monoclonal antibodies in cancer therapy
2012
Cancer Cell Metabolism: Warburg and Beyond
2008 Standout
The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases
2015
Dendritic cells: versatile controllers of the immune system
2007 StandoutNobel
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
2013 Standout
NKT cells: what's in a name?
2004
Self-antigen-Driven Activation Induces Instability of Regulatory T Cells during an Inflammatory Autoimmune Response
2013
Follicular B helper T cells in antibody responses and autoimmunity
2005
MUC1: a multifaceted oncoprotein with a key role in cancer progression
2014
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
2004 Standout
Next-generation regulatory T cell therapy
2019
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline
2009
Immunity, Inflammation, and Cancer
2010 Standout
Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view
2007
CD22 as a target of passive immunotherapy
2003
Monoclonal antibodies as therapeutic agents for cancer
2004
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
2015 Standout
Cancer immunotherapy comes of age
2011 StandoutNature
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
Immunotherapy: past, present and future
2003
Normal human dermis contains distinct populations of CD11c+BDCA-1+ dendritic cells and CD163+FXIIIA+ macrophages
2007 StandoutNobel
TREG-cell therapies for autoimmune rheumatic diseases
2014 StandoutNobel
Ligand-targeted therapeutics in anticancer therapy
2002
PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells
2013
Current strategies in the management of hormone refractory prostate cancer
2003
The Mechanistic Links Between Proteasome Activity, Aging and Agerelated Diseases
2014
HLA-Mismatched Renal Transplantation without Maintenance Immunosuppression
2008 Standout
Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer
2004
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Monoclonal antibodies for cancer immunotherapy
2009
Mixed chimerism and immunosuppressive drug withdrawal after hla-mismatched kidney and hematopoietic progenitor transplantation1
2002
Protein Sequence Editing of SKN-1A/Nrf1 by Peptide:N-Glycanase Controls Proteasome Gene Expression
2019 StandoutNobel
Synthesis of Heterobifunctional Protein Fusions Using Copper‐Free Click Chemistry and the Aldehyde Tag
2012 StandoutNobel
CD1-dependent dendritic cell instruction
2002
Bicalutamide Functions as an Androgen Receptor Antagonist by Assembly of a Transcriptionally Inactive Receptor
2002
The role of interleukin-2 during homeostasis and activation of the immune system
2012
Adoptive Immunotherapy for Cancer or Viruses
2014
The Regulatory Role of Vα14 NKT Cells in Innate and Acquired Immune Response
2003
Increased Expression of Genes Converting Adrenal Androgens to Testosterone in Androgen-Independent Prostate Cancer
2006 Standout
Taking regulatory T cells into medicine
2021 StandoutNobel
Cross-presentation of glycolipid from tumor cells loaded with α-galactosylceramide leads to potent and long-lived T cell–mediated immunity via dendritic cells
2007 StandoutNobel
Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model
2016 StandoutNobel
New Strategies for Fluorescent Probe Design in Medical Diagnostic Imaging
2009 Standout
Targeting the bone marrow microenvironment in multiple myeloma
2014
Advances in targeted therapeutic agents
2010
Effective Cancer Therapy Through Immunomodulation
2005
Activation of Natural Killer T Cells by α-Galactosylceramide Rapidly Induces the Full Maturation of Dendritic Cells In Vivo and Thereby Acts as an Adjuvant for Combined CD4 and CD8 T Cell Immunity to a Coadministered Protein
2003 StandoutNobel
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
2011 StandoutScience
Differential Requirement for CD70 and CD80/CD86 in Dendritic Cell-Mediated Activation of Tumor-Tolerized CD8 T Cells
2012
Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy With Mitumprotimut-T and Granulocyte-Macrophage Colony-Stimulating Factor After Rituximab in Patients With Follicular Lymphoma
2009
Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag
2009 StandoutNobel
Drug Delivery Systems: Entering the Mainstream
2004 StandoutScience
A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911
2003
Regulation of antitumour immunity by CD1d-restricted NKT cells
2004
A Reversible Defect in Natural Killer T Cell Function Characterizes the Progression of Premalignant to Malignant Multiple Myeloma
2003
Glycolipid α-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice
2006 StandoutNobel
Dendritic cell maturation by innate lymphocytes
2005 StandoutNobel
Proenkephalin+regulatory T cells expanded by ultraviolet B exposure maintain skin homeostasis with a healing function
2020 StandoutNobel
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+regulatory T cells, evoking antitumor immune responses in humans
2013 StandoutNobel
Immunotherapy: Bewitched, Bothered, and Bewildered No More
2004 StandoutScienceNobel
Regulatory roles of IL-10–producing human follicular T cells
2019 StandoutNobel
Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma
2017
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
Multiple Myeloma
2011 Standout
Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis
2005
CD1: Antigen Presentation and T Cell Function
2004
Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients
2005 StandoutNobel
Immune Therapy for Cancer
2008
Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial
2002
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Functionally Distinct Subsets of CD1d-restricted Natural Killer T Cells Revealed by CD1d Tetramer Staining
2002
Regulatory T cells in inflammatory skin disease: from mice to humans
2019
Works of Robin Joyce being referenced
Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma
2013
MUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells
2013
Yttrium 90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Produces High Response Rates and Durable Remissions in Patients with Previously Treated B-Cell Lymphoma
2004
Bendamustine is effective therapy in patients with rituximab‐refractory, indolent B‐cell non‐Hodgkin lymphoma
2009
PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine
2011
Lenalidomide enhances anti-myeloma cellular immunity
2012
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
2011
HIGH DOSE BICALUTAMIDE FOR ANDROGEN INDEPENDENT PROSTATE CANCER: EFFECT OF PRIOR HORMONAL THERAPY
1998
Cutting Edge: A Major Fraction of Human Bone Marrow Lymphocytes Are Th2-Like CD1d-Reactive T Cells That Can Suppress Mixed Lymphocyte Responses
2001
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
2002
Multicenter Clinical Trial of Bortezomib in Relapsed/Refractory Waldenstrom's Macroglobulinemia: Results of WMCTG Trial 03-248
2007